Health officials were told Monday (15) that the use of the booster dose against Govit-19 in the United Kingdom should be extended to people between the ages of 40 and 49, an earlier attempt by the government to boost the population’s immunity. Winter.
Currently, members of the population and risk group over the age of 50 and health professionals can get the booster, and the Joint Committee on Immunization and Immunization (JCVI) is said to be available.
The recommendation comes from a study released by the UK Health Safety Agency that the booster dose provides more than 90% protection against the symptomatic Covit-19 in people 50 years of age and older.
“Booster shots for more vulnerable adults – and second shots in young people – are important ways to increase our defense against Covit-19,” said Wei Shen Lim, head of the JCVI for immunization. “These vaccines will help extend our security until 2022.”
The UK mainly uses Pfizer-BioNTech and Moderna needles in booster releases, with people qualifying 6 months after the second injection.
The real-world study found that protection against the symptoms of Govit-19 after the booster dose was 93.1% for those who were initially vaccinated with the Astrogenogen vaccine and 94% for those who were initially vaccinated with the Pfizer vaccine.
However, the panel declined to recommend an additional dose for those under the age of 40, saying there was no strong evidence of a reduction in protection against severe COV-19 at this age.
Prime Minister Boris Johnson is leaning on the immunization campaign and trying to withstand the winter pressures on hospitals without seeking another lock.
“Internet addiction in terminals. Award-winning beer expert. Travel expert. General analyst.”